James Yarmolinsky

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Angiotensin Converting Enzyme

Genome Wide Association

Prostate Cancer

Top Venues

Journal of the National Cancer Institute

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

James Yarmolinsky, Joanna Tzoulaki, Marc J Gunter, Ruth C Travis, George Davey Smith, Karl Smith-Byrne
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers. Journal of the National Cancer Institute 116 (5) (2024)
James Yarmolinsky, Joanna Tzoulaki, Marc J Gunter, Ruth C Travis, George Davey Smith, Karl Smith-Byrne
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers. Journal of the National Cancer Institute 116 (5) (2024)
James Yarmolinsky, Joanna Tzoulaki, Marc J Gunter, Ruth C Travis, George Davey Smith, Karl Smith-Byrne
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers. Journal of the National Cancer Institute 116 (5) (2024)
Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire Marie Perks, null null, George Davey Smith, Tom R Gaunt, Tom G Richardson
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS medicine 20 (1) (2023)
Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire Marie Perks, null null, George Davey Smith, Tom R Gaunt, Tom G Richardson
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS medicine 20 (1) (2023)
Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire Marie Perks, null null, George Davey Smith, Tom R Gaunt, Tom G Richardson
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS medicine 20 (1) (2023)
Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire Marie Perks, null null, George Davey Smith, Tom R Gaunt, Tom G Richardson
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS medicine 20 (1) (2023)
Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire Marie Perks, null null, George Davey Smith, Tom R Gaunt, Tom G Richardson
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS medicine 20 (1) (2023)
James Yarmolinsky, Christopher I Amos, Rayjean J Hung, Victor Moreno, Kimberley Burrows, Karl Smith-Byrne, Joshua R Atkins, Paul J Brennan, null null, James D McKay, Richard M Martin, George Davey Smith
Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk. International journal of cancer 151 (12) (2022)
James Yarmolinsky, Virginia Díez-Obrero, Tom G Richardson, Marie Pigeyre, Jennifer Sjaarda, Guillaume Paré, Venexia M Walker, Emma E Vincent, Vanessa Y Tan, Mireia Obon-Santacana, Demetrius Albanes, Jochen Hampe, Andrea Gsur, Heather Hampel, Rish K Pai, Mark E Jenkins, Steven Gallinger, Graham Casey, Quan Long, Christopher Ian Amos, null null, null null, null null, George Davey Smith, Richard M Martin, Victor Moreno
Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS medicine 19 (2) (2022)
Timothy Robinson, Richard M Martin, James Yarmolinsky
Mendelian randomisation analysis of circulating adipokines and C-reactive protein on breast cancer risk. International journal of cancer 147 (6) (2020)